Literature DB >> 10210327

Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.

C A London1, S J Galli, T Yuuki, Z Q Hu, S C Helfand, E N Geissler.   

Abstract

Spontaneous mast cell tumors (MCT) are the most common malignant neoplasm in the dog, representing between 7% and 21% of all canine tumors, an incidence much higher than that found in humans. These tumors often behave in an aggressive manner, metastasizing to local lymph nodes, liver, spleen, and bone marrow. The proto-oncogene c-kit is known to play a critical role in the development and function of mast cells. Point mutations in the kinase domain of c-kit leading to tyrosine phosphorylation in the absence of ligand binding have been identified in three mastocytoma lines, (P815, RBL, and HMC-1), and some human patients with various forms of mastocytosis. We now demonstrate that although c-kit derived from canine MCT did not contain the previously described activating point mutations, 5 of the 11 tumors analyzed possessed novel mutations consisting of tandem duplications involving exons 11 and 12. We also show that one such duplication, detected in a canine mastocytoma cell line, was associated with constitutive phosphorylation of c-kit protein (KIT), suggesting that these mutations may contribute to the development or progression of canine MCT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210327     DOI: 10.1016/s0301-472x(98)00075-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  47 in total

1.  AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Authors:  Tzu-Yin Lin; Joelle Fenger; Sridhar Murahari; Misty D Bear; Samuel K Kulp; Dasheng Wang; Ching-Shih Chen; William C Kisseberth; Cheryl A London
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

2.  Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.

Authors:  S Rodriguez; K Fadlalla; T Graham; B Tameru; C D Fermin; T Samuel
Journal:  J Comp Pathol       Date:  2012-01-30       Impact factor: 1.311

3.  Generation and characterization of novel canine malignant mast cell line CL1.

Authors:  Tzu-Yin Lin; Rachael Thomas; Pei-Chien Tsai; Matthew Breen; Cheryl A London
Journal:  Vet Immunol Immunopathol       Date:  2008-10-11       Impact factor: 2.046

4.  Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.

Authors:  Sunetra Das; Rupa Idate; Kathryn E Cronise; Daniel L Gustafson; Dawn L Duval
Journal:  Mol Cancer Ther       Date:  2019-06-07       Impact factor: 6.261

5.  Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Seyed Rashid Touni; Hamed Zamankhan Malayeri; Aram Mokarizadeh; Mehdi Pourzaer; Maryam Pourzaer; Shahram Zehtabian; Sheida Mohajer; Sharareh Ahmadi
Journal:  Tumour Biol       Date:  2014-10-15

6.  KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Authors:  Cheryl A London; Heather L Gardner; Sarah Rippy; Gerald Post; Krista La Perle; Linda Crew; Lori Lopresti-Morrow; Andrew J Garton; Gerald McMahon; Theresa M LaVallee; Richard Gedrich
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

Review 7.  Comparative oncology today.

Authors:  Melissa C Paoloni; Chand Khanna
Journal:  Vet Clin North Am Small Anim Pract       Date:  2007-11       Impact factor: 2.093

8.  Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11.

Authors:  Emmalena Gregory-Bryson; Elizabeth Bartlett; Matti Kiupel; Schantel Hayes; Vilma Yuzbasiyan-Gurkan
Journal:  BMC Cancer       Date:  2010-10-15       Impact factor: 4.430

9.  Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma.

Authors:  Irina Gramer; Martin Kessler; Joachim Geyer
Journal:  Vet Res Commun       Date:  2016-03-12       Impact factor: 2.459

10.  Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.

Authors:  Giacomo Rossi; Chiara Bertani; Subeide Mari; Carlotta Marini; Giacomo Renzoni; Gregory Ogilvie; Gian Enrico Magi
Journal:  Vet Res Commun       Date:  2013-01-13       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.